drugset / Trial / NCT00587132

Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma

NCT00587132

Phase 1/2 Terminated 4 enrolled Mayo Clinic ChiRhoClin, Inc. · collab
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

The purpose of this study is to test if secretin-enhanced CT is a useful noninvasive screening tool for pancreatic cancer in a high-risk population.

Timeline

Start
2006-11
Primary completion
2012-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Secretin Other / unclassified 0.2 ug/kg Intravenous